The Fish Oil Translation Problem: The supplement category labelled “omega-3” in most pharmacies hides a critical distinction that mainstream nutrition has only recently begun to honour. The two principal long-chain omega-3 fatty acids — EPA and DHA — target different organs, support different functions, and require markedly different doses. Buying generic fish oil is like buying generic pills: you may be ingesting the right molecule, but at the wrong dose, for the wrong target.
The biochemistry sets up the distinction. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain polyunsaturated fatty acids found primarily in fatty fish and certain algae. Both are essential for human health, both must be obtained from diet, and both have been studied extensively in cardiovascular and neurological contexts. They are not, however, interchangeable. The differences begin at the level of cellular membrane composition and propagate upward to brain structure, inflammation, and mood.
The clinical implication is that most people taking fish oil supplements are taking the wrong ratio, the wrong total dose, or both. The cost is paid in undetected sub-optimisation across cardiovascular, inflammatory, and cognitive systems.
1. The Biochemical Division of Labour
EPA and DHA do not compete; they specialise. Three distinct functional profiles emerge:
- EPA — The Anti-Inflammatory Specialist: EPA is the precursor to resolvins and E-series specialised pro-resolving mediators (SPMs). It dominates the body’s mechanism for resolving inflammation. Higher-EPA formulations have produced the strongest results in depression, cardiovascular and arthritic trials.
- DHA — The Neuronal Structural Component: DHA is the most abundant long-chain omega-3 in brain phospholipid membranes. It is essential for neuronal membrane fluidity, synaptic function, and retinal health. DHA accumulation in the developing brain is one of the most studied developmental milestones in fetal nutrition.
- EPA <> DHA Interconversion: The human body cannot efficiently convert EPA into DHA, or vice versa. Dietary intake of each is required.
The Depression Meta-Analysis: EPA Beats DHA Beats Placebo
A 2019 meta-analysis in Translational Psychiatry, pooling 26 randomised controlled trials covering more than 2,160 patients with major depressive disorder, found that omega-3 supplements significantly improved depression scores compared with placebo — but only when the formulation was EPA-dominant (greater than 60 percent EPA). Pure DHA formulations and balanced 1:1 formulations showed no statistically significant antidepressant effect. Total dose mattered too: most positive trials used at least 1 gram of EPA per day, with some using up to 2 grams. The clinical recommendation that has slowly emerged: for mood support, EPA is the active ingredient and dose is non-trivial [cite: Mocking et al., Transl Psychiatry, 2019].
2. The Cardiovascular Picture: REDUCE-IT and the EPA Pivot
The cardiovascular omega-3 story has been one of the most-debated areas in clinical nutrition. Multiple early trials of standard mixed-EPA/DHA fish oil failed to show clear mortality benefit, leading many cardiologists to dismiss omega-3 supplementation altogether. The landscape shifted in 2018 with the publication of REDUCE-IT in the New England Journal of Medicine: a trial of icosapent ethyl (a purified, high-dose EPA-only preparation) showing a 25 percent reduction in major adverse cardiovascular events in high-risk patients on statins.
The result confirmed what the depression literature had suggested independently: when omega-3 is administered as high-dose, EPA-dominant, well-characterised material, the clinical effects emerge. Mixed-ratio low-dose supplements, in contrast, often disappear into trial noise [cite: Bhatt et al., NEJM, 2018].
| Target System | Active Omega-3 | Effective Daily Dose |
|---|---|---|
| Mood / Depression | EPA-dominant (>60%) | 1–2 g EPA |
| Cardiovascular | High-dose EPA | 2–4 g EPA (REDUCE-IT) |
| Cognitive / Memory | DHA-leaning | 500 mg – 1 g DHA |
| Fetal / Early-Life | DHA-dominant | 200–300 mg DHA |
3. Why Plant-Source Omega-3 (ALA) Is Not a Substitute
Many vegetarian and vegan readers default to flaxseed, chia, or walnut sources of omega-3. These foods are rich in alpha-linolenic acid (ALA), the short-chain omega-3 that the body must convert to EPA and DHA. The conversion is famously inefficient: humans convert roughly 5–10 percent of ALA to EPA and under 1 percent to DHA, with significant individual variation.
The practical implication is that achieving therapeutic EPA or DHA blood levels through ALA alone is essentially impossible. Vegetarian readers who want clinical-grade omega-3 status need to consider algae-derived supplements, which contain EPA and DHA directly without requiring fish-source extraction.
4. How to Choose and Dose Omega-3 Correctly
The practical protocol below reflects the converging consensus of cardiology, psychiatry and nutrition literature. Doses below the stated thresholds are unlikely to produce clinical-grade effects.
- Read the EPA/DHA Label, Not the Total Fish Oil: A 1,000 mg fish oil capsule may contain only 180 mg EPA and 120 mg DHA. The total fish oil number is not the actionable figure.
- Match Dose to Goal: Mood and cardiovascular support require gram-level EPA. Cognitive and developmental support emphasise DHA. Maintenance for healthy adults: 500 mg combined EPA+DHA daily as a floor.
- Take With Fatty Meal: Omega-3 absorption is significantly higher when consumed with dietary fat. Empty-stomach dosing often results in poor uptake.
- Choose Quality: Third-party purity-tested brands (IFOS certification, NSF) ensure oxidation levels and contaminant profiles are within safe limits. Rancid fish oil is worse than no fish oil.
- Consider Algae for Vegetarians: Direct EPA and DHA from algae bypass the ALA conversion bottleneck and achieve clinical blood levels.
Conclusion: Two Molecules, Two Doses, One Conversation Most Doctors Are Not Having
The EPA/DHA distinction is no longer a frontier of nutritional biochemistry; it is the operational basis of how mainstream cardiology and psychiatry have begun to use omega-3 therapeutically. The continued sale of generic fish oil at sub-therapeutic doses represents one of the largest gaps between current evidence and current consumer practice. Closing the gap costs nothing more than reading the actual label and doubling the dose.
Are you supplementing the molecules your evidence base actually supports — or are you taking the dose your supermarket happened to put on the shelf?